29 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Swetter, Dermatologist in Stanford, CA?
Castle Connolly Top Doctor
Castle Connolly Top Doctors are doctor-nominated and selected by a physician-led research team.
What are Areas of Expertise for Dr. Swetter?
Dr. Susan Swetter, MD is a highly-rated, board-certified Dermatologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Swetter empowers patients to confidently navigate their health journey, specializing in Melanoma, Pigmented Lesions, Skin Cancer, and comprehensive wellness support. Serving the Stanford, CA community, Dr. Swetter is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Swetter go to medical school and complete their residency?
Residency: Stanford Univ Hosp, Dermatology; Moffitt Hosp Univ Of Ca, Internal Medicine | Stanford University School of Medicine | Stanford University Medical Center
Medical School: University of Pa Sch of Med, Philadelphia Pa
Is Dr. Swetter board certified as a Dermatologist?
Yes, Dr. Susan Swetter, MD is board certified by the American Board of Dermatology , American Board of Dermatology since 1994
What languages does Dr. Swetter speak?
Dr. Swetter and their clinical team can communicate with patients in the following languages:
- English
What conditions does a Dermatologist like Dr. Swetter typically treat?
As a Dermatologist, Dr. Swetter diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Swetter. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Melanoma of the Trunk
- Melanoma
- Melanoma of Scalp or Neck
- Melanoma of the Left Leg or Hip
- Malignant Melanoma of Body
- Skin Cancer on Torso
- Malignant Melanoma
- Skin Cancer (Melanoma)
- Cutaneous Melanoma
- Black Skin Cancer
- Scalp Melanoma
- Neck Melanoma
- Skin Cancer of Scalp
- Skin Cancer of Neck
- Left Leg Melanoma
- Left Hip Melanoma
- Malignant Melanoma of Left Leg
ICD-10 Codes:
- C4359: Malignant melanoma of other part of trunk
- C439: Malignant melanoma of skin, unspecified
- C434: Malignant melanoma of scalp and neck
- C4372: Malignant melanoma of left lower limb, including hip
Also known as:
- Actinic Keratosis
- Skin Condition
- Sun Exposure
- Skin Cancer Treatment (PDQ®)
- Solar keratosis
- Precancerous skin lesion
- Rough sun spots
ICD-10 Codes:
- L570: Actinic keratosis
Also known as:
- Benign Skin Growth
- Benign Tumor
- Non-cancerous skin lesion
- Skin tumor
- Skin lump
ICD-10 Codes:
- D2370: Other benign neoplasm of skin of unspecified lower limb, including hip
What procedures does a Dermatologist like Dr. Swetter typically perform?
As a Dermatologist, Dr. Swetter performs a variety of medical procedures. This procedure information is derived from anonymized insurance claims and highlights the medical procedures most commonly performed by Dr. Swetter. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Removal of Precancerous Skin Lesions
- Removal of Benign Skin Lesions
- Shaving Skin Lesion
- Skin Lesion Shave Removal (Medium)
- Skin Conditions
- Actinic Keratosis Treatment
- Premalignant Lesion Destruction
- Skin Cancer Prevention Treatment
- Cryosurgery for Skin Lesions
- Benign Skin Growth Destruction
- Skin Lesion Excision
- Electrosurgery for Skin Lesions
- Skin Lesion Shave Excision
- Mole Shaving
- Skin Growth Removal (Shave)
- Dermal Lesion Shave
- Shave Excision of Skin Lesion
- Dermal Lesion Shaving
CPT Codes:
- 17000: Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
- 17003: Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); second through 14 lesions, each (List separately in addition to code for first lesion)
- 17110: Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
- 11301: Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 0.6 to 1.0 cm
- 11302: Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 1.1 to 2.0 cm
Also known as:
- Skin Biopsy
- Skin Biopsy (Punch)
- Skin Biopsy (Additional Site)
- Shave Biopsy
- Tangential Biopsy
- Skin Lesion Biopsy
- Punch Biopsy
- Dermal Punch Biopsy
- Shave biopsy
- Tangential skin biopsy
- Scoop biopsy
CPT Codes:
- 11102: Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion
- 11104: Punch biopsy of skin (including simple closure, when performed); single lesion
- 11103: Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)
Does Dr. Swetter accept my insurance?
Dr. Swetter accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Swetter accept in Stanford, CA?
Dr. Swetter in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Alignment Healthcare
Blue Shield of California
Cigna Group
CVS Health (formerly Aetna)
Humana
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Swetter's office located?
What hospitals are Dr. Swetter affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Swetter has admitting privileges at the following hospitals:
Recognitions
Awards
Nominated – Franklin G. Ebaugh, Jr. Award (outstanding dedication to advising med
Nominated – Kaiser Award for Clinical Teaching, Stanford University School of Med
Recognition for Excellence in Teaching – Stanford University School of Medicine, 2004
Leadership Award – Melanoma Care Coalition, 2007
Humanitarian Award Recipient, Melanoma Research Foundation, 2012
Member, American Dermatological Association, 2011
President s Volunteer Service Award – President s Council on Service & Civic Participation, Corporation for, 2007
Publications
Melanoma, Version 4.2014 Featured Updates to the NCCN Guidelines, 2014
Pediatric Melanoma: Alysis of an Intertiol Registry, 2013
Activating HRAS Mutation in Agmited Spitz Nevi Arising in a Nevus Spilus., 2013
Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines, 2013
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy, 2012
Behavioral determints of successful early melanoma detection, 2012
Gender Disparities in Patients With Melanoma: Breaking the Glass Ceiling, 2012
Survival Is Not the Only Valuable End Point in Melanoma Screening, 2012
Reporting and registering nonmelanoma skin cancers: a compelling public health need, 2012
Melanoma, 2012
Guidelines of care for the magement of primary cutaneous melanoma, 2011
Reducing mortality in individuals at high risk for advanced melanoma through education, 2011
Melanoma and Melanocytic Tumors of Uncertain Malignt Potential in Children, 2010
Risk of second primary maligncies following cutaneous melanoma diagnosis: A population-based study, 2010
Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer, 2010
Efficacy of Skin Self-Examition Practices for Early Melanoma Detection, 2009
Selection criteria for genetic assessment of patients with familial melanoma, 2009
Increasing Burden of Melanoma in the United States, 2009
Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis, 2009
Impaired interferon sigling is a common immune defect in human cancer, 2009
Melanoma in Middle-aged, 2009
Melanoma, 2009
High-molecular-weight keratin stain as a complement to Melan A stain, 2008
Melanoma underreporting: Why does it happen, how big is the problem, and how do we fix it?, 2008
California medicaid Enrollment and melanoma stage at diagnosis - A population-based study, 2008
Screening, early detection, 2007
Evaluation of digital dermoscopy in a pigmented lesion clinic, 2007
Crafting a melanoma educatiol campaign to reach middle-aged and older men, 2006
Use of artificial tanning products among young adults, 2006
Sun care advertising in popular US magazines, 2006
A call for the development and implementation of a targeted tiol melanoma screening program, 2006
Sun protection factor content and warning statements for sunless tanning products, 2005
Increasing incidence of lentigo malig melanoma subtypes, 2005
Histologic similarities between lentigo malig and dysplastic nevus, 2005
Malignt Melanoma
Prevention and detection of melanoma in the primary care setting., 2005
Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical alysis of cutaneous lesions, 2004
Challenge. Epithelioid cell histiocytoma., 2003
Malignt melanoma, 2003
Current magement of melanoma: Benefits of surgical staging and adjuvant therapy, 2003
Dermatological perspectives of malignt melanoma, 2003
Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas, 2003
Positron emission tomography is superior to computed tomography for metastatic detection, 2002
Interstitial mycosis fungoides, 2002
The ratiole behind the 2002 AJCC Melanoma Staging Committee recommendations, 2001
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, 1999
Infiltrative basal cell carcinoma occurring in sites of biopsy-proven nodular basal cell carcinoma, 1998
Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, 1998
Increased proportion of aggressive, 1996
Malignt melanoma from the dermatologic perspective, 1996
Surgical margins for malignt melanoma: Another point of view, 1996
Cutaneous myiasis following travel to Belize, 1996
CUTANEOUS NODULES OF MYCOBACTERIUM, 1993
Melanoma, Version 4.2014 Featured Updates to the NCCN Guidelines, 2014
Pediatric Melanoma: Analysis of an International Registry, 2013
Role of aspirin and non-aspirin NSAIDs in preventing melanoma., 2013
Activating HRAS Mutation in Agminated Spitz Nevi Arising in a Nevus Spilus., 2013
Melanoma Survival Disadvantage in Young, Non-Hispanic White Males Compared With Females, 2013
Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women The Women's, 2013
Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines, 2013
Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma, 2012
A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy, 2012
Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?, 2012
Examining the pathways linking lower socioeconomic status and advanced melanoma, 2012
Behavioral determinants of successful early melanoma detection, 2012
Gender Disparities in Patients With Melanoma: Breaking the Glass Ceiling, 2012
Survival Is Not the Only Valuable End Point in Melanoma Screening, 2012
Reporting and registering nonmelanoma skin cancers: a compelling public health need, 2012
Melanoma, 2012
Attitudes Toward Indoor Tanning Among Users of Sunless Tanning Products, 2012
Guidelines of care for the management of primary cutaneous melanoma, 2011
Reducing mortality in individuals at high risk for advanced melanoma through education, 2011
Increases in Melanoma Among Adolescent Girls, 2011
Effect of oral sulindac on biomarkers of drug bioavailability, 2011
The Expanding Melanoma Burden in California Hispanics Importance of Socioeconomic Distribution, 2011
Interaction of Area-Level Socioeconomic Status, 2010
Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, 2010
Risk of second primary malignancies following cutaneous melanoma diagnosis, 2010
Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer, 2010
Efficacy of Skin Self-Examination Practices for Early Melanoma Detection, 2009
Selection criteria for genetic assessment of patients with familial melanoma, 2009
Increasing Burden of Melanoma in the United States, 2009
Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis, 2009
Impaired interferon signaling is a common immune defect in human cancer, 2009
Factors Associated With Physician Discovery of Early Melanoma in Middle-aged and Older Men, 2009
Gender Differences in Melanoma Awareness and Detection Practices Between Middle, 2009
Melanoma in Middle-aged, 2009
Factors Related to the Presentation of Thin, 2009
Melanoma, 2009
High-molecular-weight keratin stain as a complement to Melan A stain, 2008
Melanoma underreporting: Why does it happen, how big is the problem, and how do we fix it?, 2008
California medicaid Enrollment and melanoma stage at diagnosis - A population-based study, 2008
Primary dermal melanoma, 2008
Screening, early detection, 2007
Evaluation of digital dermoscopy in a pigmented lesion clinic, 2007
Effect of health care delivery models on melanoma thickness, 2007
Crafting a melanoma educational campaign to reach middle-aged and older men, 2006
Facial resurfacing for nonmelanoma skin cancer prophylaxis, 2006
Slow-growing nodule on the thigh - Solitary fibrous tumor (SFT), 2006
Use of artificial tanning products among young adults, 2006
Sun care advertising in popular US magazines, 2006
A call for the development and implementation of a targeted national melanoma screening program, 2006
Sun protection factor content and warning statements for sunless tanning products, 2005
Increasing incidence of lentigo maligna melanoma subtypes, 2005
Sentinel lymph node biopsy for cutaneous melanoma - The Stanford experience, 1997-2004, 2005
Histologic similarities between lentigo maligna and dysplastic nevus, 2005
Malignant Melanoma
Vaccine therapy of melanoma: an update., 2005
Prevention and detection of melanoma in the primary care setting., 2005
Melanoma in the older person, 2004
Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome, 2004
Diffuse verrucous, vascular nodules on the extremities and trunk, 2004
Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions, 2004
Kinetics and specificity of Fas ligand induction in toxic epidermal necrolysis, 2004
Primary dermal melanoma - A distinct subtype of melanoma, 2004
Challenge. Epithelioid cell histiocytoma., 2003
Malignant melanoma, 2003
Current management of melanoma: Benefits of surgical staging and adjuvant therapy, 2003
Dermatological perspectives of malignant melanoma, 2003
Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas, 2003
Increased effectiveness of targeted skin cancer screening, 2003
Positron emission tomography is superior to computed tomography for metastatic detection, 2002
Interstitial mycosis fungoides, 2002
Developing indications for the use of sentinel lymph node biopsy, 2001
The rationale behind the 2002 AJCC Melanoma Staging Committee recommendations, 2001
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, 1999
Hereditary ochronosis: Hyperpigmented skin overlying cartilaginous structures, 1999
Infiltrative basal cell carcinoma occurring in sites of biopsy-proven nodular basal cell carcinoma, 1998
Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, 1998
Dopamine-associated symmetric peripheral gangrene, 1997
Increased proportion of aggressive, 1996
Malignant melanoma from the dermatologic perspective, 1996
Surgical margins for malignant melanoma: Another point of view, 1996
Cutaneous myiasis following travel to Belize, 1996
SCLEREDEMA REVISITED - A POSTSTREPTOCOCCAL COMPLICATION, 1994
CUTANEOUS NODULES OF MYCOBACTERIUM, 1993
What is Dr. Swetter's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Swetter's National Provider Identifier (NPI) number is 1538172051.
What common questions do patients ask about Dr. Swetter?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Swetter